Momentum Group AB (publ) (STO:MMGR.B)

Achilles Therapeutics Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	177	178	170	137	116	92
Depreciation & Amortization	148	137	100	68	54	37.33
Other Operating Activities	5	-4	10	-20	1	37.33
Change in Accounts Receivable	-4	-4	26	-22	-59	68
Change in Inventory	8	8	-20	-35	-11	24
Change in Other Net Operating Assets	8	8	-26	7	68	-37.33
Operating Cash Flow	342	323	260	135	169	221.33
Operating Cash Flow Growth	21.71%	24.23%	92.59%	-20.12%	-23.64%	62.74%
Capital Expenditures	-9	-9	-12	-5	-5	-4
Cash Acquisitions	-236	-105	-424	-100	-120	-5.33
Sale (Purchase) of Intangibles	-5	-1	-	-	-	-
Investment in Securities	-	-1	-	-	-	-
Investing Cash Flow	-250	-116	-436	-105	-125	-9.33
Long-Term Debt Issued	-	5	304	56	104	-
Long-Term Debt Repaid	-	-179	-65	-51	-245	-
Total Debt Repaid	-179	-179	-65	-51	-245	-81.33
Net Debt Issued (Repaid)	-174	-174	239	5	-141	-81.33
Issuance of Common Stock	5	5	17	15	-	-
Repurchase of Common Stock	-	-	-	-87	-	-
Common Dividends Paid	-54	-54	-49	-	-	-
Other Financing Activities	150	-4	-1	-16	22	21.33
Financing Cash Flow	-73	-227	206	-83	-119	-60
Net Cash Flow	19	-20	30	-53	-75	152
Free Cash Flow	333	314	248	130	164	217.33
Free Cash Flow Growth	21.53%	26.61%	90.77%	-20.73%	-24.54%	63.41%
Free Cash Flow Margin	11.11%	10.93%	10.79%	7.48%	11.00%	19.47%
Free Cash Flow Per Share	6.74	6.36	5.03	2.61	3.25	4.30
Cash Income Tax Paid	73	73	40	59	31	-12
Levered Free Cash Flow	285	295.5	124.88	74.13	116.5	-
Unlevered Free Cash Flow	303.13	315.5	136.75	78.5	120.88	-

Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.